We have located links that may give you full text access.
Recurrent atrial flutter and atrial fibrillation after catheter ablation of the cavotricuspid isthmus: a very long-term follow-up of 333 patients.
Journal of Interventional Cardiac Electrophysiology : An International Journal of Arrhythmias and Pacing 2002 December
INTRODUCTION: Radiofrequency catheter ablation of the cavotricuspid isthmus is an effective therapy for typical atrial flutter (AFL), however, the long-term recurrence of AFL and early or late occurrence of atrial fibrillation (AF) are not well defined. This study investigated the long-term (up to 68 months) outcome of patients with typical AFL after catheter ablation of the cavotricuspid isthmus.
METHODS: This study included 380 patients with typical AFL, who received linear ablation of the cavotricuspid isthmus. They were followed up at the outpatient clinic. A questionnaire was used to evaluate the symptoms suggestive of tachyarrhythmias, and 12-lead ECG, Holter monitoring and event recorders were used to confirm the diagnosis of tachyarrhythmias.
RESULTS: At the end of study, 47 patients lost follow-up, so that 333 patients were enrolled into final analysis. Ten (3%) patients had failed ablation of typical AFL. Univariate analysis showed that left atrial dimension was the only factor related to failed ablation. During the long-term follow-up period of 29 +/- 17 months (range 7 to 68 months), 29 (9%) patients had recurrent AFL, including 15 with typical and 14 with atypical AFL. Univariate and multivariate analyses showed that incomplete isthmus block and inducible atypical AFL were the independent predictors of recurrent typical and atypical AFL, respectively. One hundred and two (31%) patients developed AF, including 48 with early occurrence of AF (within 3 months after ablation), and 54 with late occurrence of AF (greater than 3 months). Univariate and multivariate analyses showed that prior history of AF and inducible AF were independent predictors of early occurrence of AF, and prior history of AF was the only independent predictor of late occurrence of AF.
CONCLUSIONS: Linear ablation of the cavotricuspid isthmus is an effective therapy with low recurrence rate for patients with typical AFL. However, one-third patients had early or late occurrence of AF.
METHODS: This study included 380 patients with typical AFL, who received linear ablation of the cavotricuspid isthmus. They were followed up at the outpatient clinic. A questionnaire was used to evaluate the symptoms suggestive of tachyarrhythmias, and 12-lead ECG, Holter monitoring and event recorders were used to confirm the diagnosis of tachyarrhythmias.
RESULTS: At the end of study, 47 patients lost follow-up, so that 333 patients were enrolled into final analysis. Ten (3%) patients had failed ablation of typical AFL. Univariate analysis showed that left atrial dimension was the only factor related to failed ablation. During the long-term follow-up period of 29 +/- 17 months (range 7 to 68 months), 29 (9%) patients had recurrent AFL, including 15 with typical and 14 with atypical AFL. Univariate and multivariate analyses showed that incomplete isthmus block and inducible atypical AFL were the independent predictors of recurrent typical and atypical AFL, respectively. One hundred and two (31%) patients developed AF, including 48 with early occurrence of AF (within 3 months after ablation), and 54 with late occurrence of AF (greater than 3 months). Univariate and multivariate analyses showed that prior history of AF and inducible AF were independent predictors of early occurrence of AF, and prior history of AF was the only independent predictor of late occurrence of AF.
CONCLUSIONS: Linear ablation of the cavotricuspid isthmus is an effective therapy with low recurrence rate for patients with typical AFL. However, one-third patients had early or late occurrence of AF.
Full text links
Trending Papers
A Personalized Approach to the Management of Congestion in Acute Heart Failure.Heart International 2023
Potential Mechanisms of the Protective Effects of the Cardiometabolic Drugs Type-2 Sodium-Glucose Transporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure.International Journal of Molecular Sciences 2024 Februrary 21
2024 ACC Expert Consensus Decision Pathway for Treatment of Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee.Journal of the American College of Cardiology 2024 March 3
The Effect of Albumin Administration in Critically Ill Patients: A Retrospective Single-Center Analysis.Critical Care Medicine 2024 Februrary 8
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app